Log in

Start Your Membership Now

The Colorado Department of Health Care Policy & Financing (HCPF) launched two Medicaid value-based contracts, effective January 1, 2022, with drug manufacturer Novartis. One contract is with Novartis Gene Therapies for its Zolgensma drug therapy used to treat spinal muscular atrophy (SMA). The other is with Novartis Pharmaceuticals Corporation for its Entresto drug therapy used to treat heart failure. These are HCPF’s first value-based contracts for the Colorado Medicaid pharmacy program.

Both contracts hold Novartis financially accountable for meeting the clinical outcomes demonstrated in clinical trials. However, HCPF has not publicly released the target clinical outcomes.

The . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: